Pharsight

Sunovion Pharms Inc patents expiration

1. Aptiom patents expiration

APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9206135 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11364247 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 1 month from now)

US10675287 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 1 month from now)

US10695354 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 1 month from now)

US10702536 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 1 month from now)

US9643929 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(2 years from now)

US9763954 SUNOVION PHARMS INC Therapeutical uses of eslicarbazepine
Sep, 2028

(4 years from now)

US9566244 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(4 years from now)

US10912781 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(4 years from now)

US8372431 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Apr, 2030

(6 years from now)

US9750747 SUNOVION PHARMS INC Treatments involving eslicarbazepine acetate or eslicarbazepine
Aug, 2032

(8 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have bee...

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents

2. Kynmobi patents expiration

KYNMOBI's oppositions filed in EPO
KYNMOBI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9931305 SUNOVION PHARMS INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Feb, 2022

(2 years ago)

US10888499 SUNOVION PHARMS INC Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
Feb, 2022

(2 years ago)

US9855221 SUNOVION PHARMS INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2022

(2 years ago)

US11077068 SUNOVION PHARMS INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2022

(2 years ago)

US8663687 SUNOVION PHARMS INC Film compositions for delivery of actives
Feb, 2023

(1 year, 1 month ago)

US8765167 SUNOVION PHARMS INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(a month ago)

US8603514 SUNOVION PHARMS INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(4 days from now)

US10821074 SUNOVION PHARMS INC Sublingual and buccal film compositions
Aug, 2029

(5 years from now)

US9044475 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US9326981 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US10420763 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US9283219 SUNOVION PHARMS INC Sublingual films
Jun, 2030

(6 years from now)

US9669019 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US9669021 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US8414922 SUNOVION PHARMS INC Sublingual films
Dec, 2031

(7 years from now)

US8846074 SUNOVION PHARMS INC Sublingual films
Dec, 2031

(7 years from now)

US11419769 SUNOVION PHARMS INC Sublingual films
Dec, 2031

(7 years from now)

US10449146 SUNOVION PHARMS INC Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
Apr, 2036

(12 years from now)

US10959943 SUNOVION PHARMS INC Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
Apr, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

More Information on Dosage

KYNMOBI family patents

Family Patents

3. Latuda patents expiration

LATUDA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE45573 SUNOVION PHARMS INC Process for producing imide compound
Jun, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975 SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Feb, 2024

(a month ago)

US9815827 SUNOVION PHARMS INC Agent for treatment of schizophrenia
Feb, 2024

(a month ago)

US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Aug, 2024

(4 months from now)

USRE45573

(Pediatric)

SUNOVION PHARMS INC Process for producing imide compound
Dec, 2025

(1 year, 8 months from now)

US9907794 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US9555027 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US8729085 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US8883794 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US8883794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(2 years from now)

US9907794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(2 years from now)

US8729085

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(2 years from now)

US9827242 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(7 years from now)

US9259423 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(7 years from now)

US9259423

(Pediatric)

SUNOVION PHARMS INC Method of treatment for mental disorders
Nov, 2031

(7 years from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2010

Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; Treatment of ...

Dosage: TABLET;ORAL

How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage

LATUDA family patents

Family Patents